← board
MIST
Milestone Pharmaceuticals Inc.distress 1/10 · well-funded / low risk$1.19+0%today-60% from 52w high
Lead: paroxysmal supraventricular tachycardia (PSVT)
Revenue
pre-revenue
Liquidity
$184M
Runway
3.6 yrs
Shares 1y
+47%
Price & events
-40.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.3%
1D
-3.7%
1W
-8.2%
1M
-36.1%
3M
-39.7%
6M
-25.4%
1Y
-19.9%
2Y
-78.4%
5Y
-82.3%
All
Overview
- Market Cap
- $148.65M
- Enterprise Value
- $135.53M
- Volume
- 54.87K
- 52 Week Range
- $1.01 – $2.95
- Total Shares
- 124.50M
- Float Shares
- 116.91M
- Short %
- 10.19%
- % Held by Insiders
- 0.70%
- % Held by Institutions
- 34.69%
- RVOL
- 0.04x
- Beta
- 0.97
Pipeline stages · 1 programs
Etripamil NS 70 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-04-10 | Phase 3 | Etripamil NS 70 mg | Paroxysmal Supraventricular Tachycardia | 130 | completed |
Catalyst news & presentations · 9
- first quarter of 2027Guided 70%chmp opinionCHMP (EU)etripamil · Decision on approval expected by Q1 2027.SEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-01-12partnershipetripamil · Closed sale of royalty interest to RTW for $75MSEC 8-K
- January 6, 2026filing acceptanceFiled (NDA/BLA)etripamil · EMA accepted Marketing Authorization Application for etripamil nasal spray.SEC 8-K
- December 13, 2025PDUFAPDUFAetripamil · PDUFA target action date for CARDAMYST nasal spraySEC 8-K
- 2025-07-10partnershipetripamil · Royalty Purchase Agreement with RTW extended to December 31, 2025, contingent on FDA approvalSEC 8-K
- 2025-03-28crletripamil · Complete Response Letter for NDA; CMC issues (nitrosamine impurities and facility inspection)SEC 8-K
- March 27, 2025PDUFAPDUFAetripamil · PDUFA date for CARDAMYST (etripamil) nasal spray NDASEC 8-K
- prior to September 6, 2024trial initiationsecondaryAppointment of third new independent directorSEC 8-K
Approved drugs (1)
- CARDAMYSTETRIPAMIL2025 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $6 (+430% upside) · 6 analysts
- 2026-05-14Wells FargoOverweight
- 2026-01-06HC Wainwright & Co.Buy
- 2025-12-16Wells FargoOverweight
- 2025-12-15TD CowenHold → Buy
- 2025-12-15HC Wainwright & Co.Buy
- 2025-09-11Wells FargoOverweight
Competitors — paroxysmal supraventricular tachycardia (PSVT)
- none identified
Recent news
- 2026-07-19Milestone Pharmaceuticals (MIST) Q4 2024 earnings summary - Quartr
- 2026-07-14Price to book forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
- 2026-07-08Milestone Pharmaceuticals (MIST) Investor update Summary - Quartr
- 2026-07-02Milestone lures six new employees with 288,000 options - Stock Titan
- 2026-06-25MIST Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-15Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
- 2026-06-12Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 - Stock Titan
- 2026-06-09Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST) - Seeking Alpha
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.